What You Should Know:
– 4G Clinical, a cutting-edge randomization and trial supply management (RTSM) company, today announced it has entered into an agreement to receive a growth equity investment of over $230MM from Goldman Sachs Asset Management (“Goldman Sachs”).
– Founded in 2015, 4G Clinical’s Prancer RTSMⓇ enables life sciences companies to reach First Patient In (FPI) up to 50% faster than other providers and implement mid-study changes more efficiently. 4G Clinical’s clinical supply optimization solution, 4C Supply, incorporates real-time RTSM actuals to prevent stock-outs and reduce drug waste. To date, 4G Clinical supports clinical trials for over 100 biotech and pharma clients globally.
– The company will use the investment to fund 4G Clinical’s continued global expansion, support the growing demand for 4G’s products, and to further the company’s mission of bringing crucial medicines to those who need them, faster.